Skip to main content


You are here

Profectus BioSciences Presents Data at Filovirus Medical Countermeasures Meeting

Monday, September 23, 2013

Profectus BioSciences Inc., a leader in developing next generation vaccines for high value targets in biodefense, infectious, and emerging diseases, presented on the development of its rVSV‐vectored Ebola and Marburg virus vaccine at the Filovirus Medical Countermeasures (MCM) Workshop held in the National Institutes of Health (NIH) Fishers Lane Conference Center in Rockville, MD.

Read the full press release